Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective.

van Leeuwen, Roelof W F; van Gelder, Teun; Mathijssen, Ron H J; Jansman, Frank G A

van Leeuwen, Roelof W F; van Gelder, Teun; Mathijssen, Ron H J; Jansman, Frank G A.

Afiliación

van Leeuwen RW; Department of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, Netherlands.
van Gelder T; Department of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, Netherlands; Department of Internal Medicine, Erasmus University Medical Centre, Rotterdam, Netherlands.
Mathijssen RH; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, Netherlands.
Jansman FG; Department of Clinical Pharmacy, Deventer Hospital, Deventer, Netherlands; Department of Pharmacotherapy and Pharmaceutical Care, University of Groningen, Groningen, Netherlands. Electronic address: f.g.a.jansman@dz.nl.

Lancet Oncol ; 15(8): e315-26, 2014 Jul.

Article en En | MEDLINE | ID: mdl-24988935

Asunto(s)

Antineoplásicos/farmacocinética; Interacciones Farmacológicas; Absorción Intestinal; Inhibidores de Proteínas Quinasas/farmacocinética; Antineoplásicos/efectos adversos; Antineoplásicos/metabolismo; Disponibilidad Biológica; Humanos; Conciliación de Medicamentos; Inhibidores de Proteínas Quinasas/efectos adversos; Inhibidores de Proteínas Quinasas/metabolismo

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inhibidores de Proteínas Quinasas / Interacciones Farmacológicas / Absorción Intestinal / Antineoplásicos Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2014 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google